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The objective of this study was to examine if clinical and histopathological variables in patients
with oral lichen planus (OLP), oral lichenoid lesions (OLL), and generalized stomatitis display
different cytokine profiles and if concomitant contact allergy influences this profile. Forty‐nine
patients and 29 healthy age‐ and gender‐matched subjects were included. Demographic and
clinical data immunohistochemical findings in mucosal specimens, results of contact allergy
testing, and serum levels of tumor necrosis factor‐α, interferon‐γ, interleukin (IL)‐6, IL‐10,
IL‐12p40, and IL‐12p70 were analyzed and compared between groups. Nineteen patients had
OLP, primarily with ulcerative lesions on the buccal mucosa, 19 patients had OLL, and 11 patients
had generalized stomatitis. All patients had oral symptoms, mainly stinging and burning. Nineteen
patients and 10 healthy subjects had contact allergies, primarily to fragrance ingredients. Patient
groups did not differ with regard to oral symptoms, clinical pattern of the lesions, or contact
allergy. Serum cytokine levels did not differ between the different patient groups and were not
related to histopathological findings. The patients had higher levels of IL‐6 than the healthy
subjects. Interferon‐γ, IL‐12p40, and IL‐12p70 were below detection limit. Our findings indicate
that OLP, OLL, and generalized stomatitis cannot be discriminated by means of the selected
serum cytokines, and that the presence of concomitant contact allergy does not influence the
cytokine expression.
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Oral lichen planus (OLP) is a chronic, inflammatory, and immune‐
mediated oral‐mucosal disease affecting 0.5% to 2% of the adult
population (Axéll & Rundquist, 1987; Bowers, Sexton, & Sugerman,
2000; McCartan & Healy, 2008; Pinto, Khalaf, & Miller, 2015). OLP
is about twice as common in women as in men and mostly affects
middle aged and older adult (Kovac‐Kovacic & Skaleric, 2000; Scully
et al., 1998). The buccal mucosa, the margins of the tongue, and the
gingivae are the most commonly involved sites. Clinically, OLP may
present as reticular, erythematous, erosive or ulcerative, plaquelike,
bullous, and papular lesions of which the latter two are considered- - - - - - - - - - - - - - - - - - - - - - - - - - -
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Thorn, Holmstrup, Rindum, & Pindborg, 1988). The etiology and
pathogenesis remain unclear, but T‐lymphocytes are believed to be
involved. The mechanisms that trigger the T‐lymphocytes to enter
the oral epithelium and to form the subepithelial inflammatory
infiltrate, and the triggering mechanisms underlying basal
keratinocyte apoptosis are still not clarified. It may involve both
antigen‐specific and non‐specific mechanisms. The inflammatory
infiltrate mainly consists of activated cytotoxic (CD8+)‐T‐lympho-
cytes, which are assumed to interact with CD4+‐T‐lymphocytes,
Langerhans cells, macrophages (CD68+), and basal keratinocytes
(Sugerman et al., 2002).- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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pathological criteria (Kramer, Lucas, Pindborg, & Sobin, 1978; van der
Meij & van der Waal, 2003). Lesions that clinically and histopathologi-
cally resemble OLP may develop as a reaction to certain systemic
medications (Porter & Scully, 2000) or dental materials (Bolewska,
Holmstrup, Møller‐Madsen, Kenrad, & Danscher, 1990; Lind, 1988;
Scully & Carrozzo, 2008) and are referred to as oral lichenoid lesions
(OLL). Oral hygiene products containing aroma substances may also
trigger lichenoid contact allergic reactions (Miller, Gould, & Bernstein,
1992; Yiannias, el‐Azhary, Hand, Pakzad, & Rogers, 2000). Generalized
stomatitis is characterized as a more diffuse reaction varying from
barely visible to a bright red erythematous lesion in addition to erosive
and hyperkeratotic lesions occurring anywhere in the oral mucosa
(Isaac‐Renton, Li, & Parsons, 2015). Generalized stomatitis may derive
from allergic reactions to aroma substances in oral hygiene products as
well as metals used in dentistry (Isaac‐Renton et al., 2015).
Cytokines play an important role in both innate and adapted
immune responses, and changes in the synthesis of cytokines may ini-
tiate immune responses that can lead to development of various
inflammatory, immune‐mediated diseases. Changes in the expression
of cytokines may reflect the extent of immune dysregulation and vari-
ous roles of cytokines in the pathogenesis of inflammatory diseases
such as OLP (Lu, Zhang, Sun, Du, & Zhou, 2013; Moudgil & Choubey,
2011). A number of studies have shown that the expression pattern
of various inflammation‐related cytokines, including tumor necrosis
factor (TNF)‐α, interferon (IFN)‐γ, and interleukin (IL‐)‐1, 2, 4, 5, 6, 8,
10, 12, 17, 22, in lesions, saliva, serum, and peripheral blood mononu-
clear cells (PBMCs) from patients with OLP differs from that seen in
healthy control subjects (Dan et al., 2011; de Brito Monteiro et al.,
2015; Kaur & Jacobs, 2015; Kondo & Urisu, 2009; Liu et al., 2014;
Malekzadeh, Robati, Yousefimanesh, Ghafourian Boroujerdnia, &
Nadripour, 2015; Pekiner, Demirel, Borahan, & Ozbayrak, 2012;
Piccinni et al., 2014; Simark‐Mattsson et al., 1999; Wang, Zhou, Fu,
Wang, & Zhou, 2015; Zhou et al., 2009). TNF‐α is one the most studied
cytokines in OLP and is believed to play an important role in the
immune regulation of OLP (Pezelj‐Ribaric et al., 2004). Levels of TNF‐α
have been found increased in OLP lesions and saliva, decreased in
PBMCs, whereas findings regarding the levels in serum are inconsis-
tent (Lu et al., 2013; Ma et al., 2016; Sugerman et al., 2002). INF‐γ is
produced by T‐helper Type 1 (Th1) cells, whereas IL‐10 is produced
by Th2 cells (Bai et al., 2008; Piccinni et al., 2014; Rhodus, Cheng, &
Ondrey, 2007). INF‐γ is assumed to be involved in the activation of
CD8+ T lymphocytes and to maintain major histocompatibility class II
molecules on keratinocytes (Ghallab, el‐Wakeel, & Shaker, 2010;
Sugerman et al., 2002). IL‐20 differentiates naïve T cells into Th1
effector cells, induces production of INF‐γ from natural killer cells
and T cells and enhances the cytotoxicity of natural killer cells and
CD8+ T‐lymphocytes (Gee, Guzzo, Che Mat, Ma, & Kumar, 2009).
IL‐12p40 expression has been found increased in OLP lesions,
whereas the levels in serum are unknown (Pan, Cai, & Yu, 2011).
Clinically, and in many cases also histopathologically, it may be
difficult to discriminate between OLP, OLL, and generalized stomatitis.
However, characterization of the potential differences has important
clinical and therapeutic implication, for example, considering the
potential malignant transformation of some lesions and the potentialinvolvement of allergy. The purpose of this cross‐sectional study was
therefore to clarify whether the profile of selected serum cytokines
differ between patients with OLP, OLL, and generalized stomatitis
and between patients and healthy control subjects, and whether
variations in clinical and histopathological findings as well as the
presence of concomitant contact allergy have an impact on the serum
cytokine profile.2 | MATERIALS AND METHODS
2.1 | Study participants
This study was approved by the ethics committee of the Capital
Region of Denmark (No. H‐3‐2013‐033) and conducted according to
the Declaration of Helsinki. Informed consent was obtained from all
included participants.
One hundred thirty‐four consecutive patients referred the Clinic
for Oral Medicine, Department of Odontology, Faculty of Health and
Medical Sciences, University of Copenhagen, due to symptoms and
signs of oral mucosal diseases were screened for inclusion in the
study. Fifty‐two Caucasian patients were enrolled of whom 49 com-
pleted all examinations. The remaining patients were excluded due
to other conditions than OLP, OLL, and generalized stomatitis,
including suspicion of medication‐induced OLL. None of the patients
had severe periodontitis, ongoing infections, systemic autoimmune
diseases, or received immunosuppressive therapy. Twenty‐nine
healthy age‐ and gender‐matched subjects were recruited via the
Danish website for research study subjects, www.forsoegsperson.
dk. The exclusion criteria for these subjects were past or current
history of systemic and oral diseases as well as intake of medication.
Four persons taking antihypertensives were matched to the patients
regarding age, gender, and type of antihypertensive drug as it
proved difficult to recruit nonmedicated control subjects above the
age of 65 years.
An oral smear was taken from all participants before inclusion in
order to exclude oral candidiasis as it may mimic other mucosal lesions.
Besides, a superimposed candidiasis may masquerade the pattern of
OLP lesions and cause the oral symptoms. The smear was stained with
Periodic acid‐Schiff and evaluated cytologically for presence of yeast
hyphae and spores. Oral candidiasis was present in 11 patients, but
in none of the healthy subjects. All of them were treated with nystatin
for 4 weeks, before inclusion. However, the antifungal treatment had
no impact on their oral symptoms, but a repeated smear showed that
the hyphae and spores were eliminated.
All patients had oral symptoms and were diagnosed with OLP,
OLL, or generalized stomatitis. Clinically, the patients with OLP
and OLL were characterized by various combinations of reticular
(white striations), erythematous, ulcerative, and plaquelike
(homogenous, slightly elevated white patches) lesions, and some of
the lesions being in close proximity of one or more dental restorations.
The patients diagnosed with generalized stomatitis were characterized
by having a more diffuse, widespread oral mucosal erythema. One
examiner (K. R. L.) performed the oral clinical examination, calibrated
against an experienced clinical examiner (A. M. L. P.). The localization,
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were taken.
All participants underwent a mucosal biopsy in order to confirm to
the diagnosis and to confirm that the healthy control subjects had
normal oral mucosa. The histological features of OLP included a well‐
defined, bandlike zone of inflammatory infiltrate, confined to the
superficial lamina propria, and liquefactive degeneration of the basal
cell layer according to the criteria of van der Meij and van der Waal
(2003). None of the patients were treated for their symptoms before
or during the study.
All participants underwent patch testing for contact allergy at
the Department of Dermatology and Allergy, Gentofte University
Hospital. Patch testing to the European baseline series, a toothpaste
series, and a dental material series were done according to
the European Society of Contact Dermatitis guidelines (Johansen
et al., 2015).
All participants were asked standardized questions regarding
past and current systemic diseases, including allergies, daily intake
of medication, habits regarding alcohol consumption, tobacco
smoking, and oral hygiene. Data on smoking habits was used to
categorize participants as never smokers, former smokers, and
current smokers. Data on alcohol consumption was used to pool
the participants in groups of never consuming alcohol, occasionally,
or daily consumption of alcohol. They were also being questioned
about symptoms of the oral mucosa such as itching, burning and
roughness, dysgeusia, and xerostomia (Larsen, Johansen, Reibel,
Zachariae, & Pedersen, 2017). Additionally, measurements of
unstimulated and paraffin‐chewing‐stimulated whole saliva flow
rates and stimulated parotid saliva flow rates were performed
(Larsen, Johansen, Reibel, Zachariae, & Pedersen, 2017).
Peripheral blood samples were obtained from all participants. The
samples were centrifuged to separate to the serum, and then por-
tioned and stored at −80 °C until further analysis. The determination
of the different types of serum cytokines were performed using
enzyme‐linked immunosorbent assays for determination of human
TNF‐α, INF‐γ, IL‐6, IL‐10, IL‐12p40, and IL‐12p70, following the
protocol provided by R&D Systems ((DuoSet® ELISA Development
Systems, R&D Systems, UK). The recovery rates varied between 57%
and 95%.2.2 | Statistical analysis
The SPSS Version 22 (IBM) was used for statistical analysis. Mann–
Whitney U‐test was used for comparison of the concentrations of
TNF‐α, INF‐γ, IL‐6, IL‐10, IL‐12p40, and IL‐12p70 between the
patient groups and patient group and healthy control group. The
Spearman rank correlation test was used to explore associations
between levels of serum cytokines and clinical and histopathological
parameters. Fischer's exact test was used for evaluation of differ-
ences in the distribution between the patient groups, including those
with or without a concomitant contact allergy and the healthy con-
trol group. Associations between variables were analyzed by the
Spearman rank order correlation test. Statistical significance was
set at a p value < .05.3 | RESULTS
Nineteen patients were diagnosed with OLP and another 19 patients
with OLL. Eleven patients had generalized stomatitis. Table 1 shows
the demographic and medical data of the patients with OLP, OLL, and
generalized stomatitis. About 85% of the participants were women with
an average age of about 61 years (range 31–77 years). The patients with
generalized stomatitis were slightly older, that is, 65 years than the OLP
and OLL patients. Three patients and four healthy subjects smoked
cigarettes on a daily basis (mean 21.5 and 17.3 smoking pack years,
respectively). Seven patients and 11 healthy control subjects reported
that they had a daily consumption of alcohol. There were no differences
between the groups with regard to smoking and alcohol habits.
In the patient group as a whole, 85.7% reported having one or
more medical condition or disease (median 2, range 1–12) of which
the most prevalent included recurrent labial herpes infection, hyper-
tension, osteoarthritis, contact dermatitis, and asthma. Furthermore,
six patients had pollen allergy, seven had contact allergy to nickel,
and five had allergy to fragrance ingredients, whereas none of the
healthy subjects reported allergies (Larsen, Johansen, Reibel,
Zachariae, Rosing et al., 2017).
In the patient group as a whole, 65.3% reported daily intake of
prescribed medication (median 2, range 1–10), mostly antihyperten-
sives. About one third of the patients (n = 16) had a daily intake of
more than two different types of medication. There were no associa-
tions between age, gender, and the number of medical conditions or
diseases and the number of medication taken on daily basis.
Patch testing revealed that 19 patients (38.8%) and 10 (34.5%)
healthy control subjects had contact allergy, mainly to fragrance mix.
The patients, and especially those with OLP and OLL, had significantly
more contact allergy to aroma substances in oral hygiene products
than the healthy control subjects (p = .02 and p = .01). Spearmint
was the most common allergen in the patient group and cassia oil in
the healthy control group (Larsen, Johansen, Reibel, Zachariae, Rosing
et al., 2017).
The patients had more complaints of xerostomia and more severe
xerostomia than the healthy control subjects (p < .001). About 47% of
the patients reported symptoms of xerostomia varying from slight to
severe symptoms,whereas the healthy subjects reported slight sensation
of dry mouth, and mainly related to snoring or mouth breathing. The
frequency of xerostomia did not differ between patients with OLP,
OLL, and generalized stomatitis and patientswith andwithout a concom-
itant contact allergy. There were no associations between the presence
and severity of xerostomia and age, gender, number of medical condi-
tions or diseases, including allergies, or the number of medications taken
on a daily basis. No differences could be found between the patient
groups and the healthy control group and those with and without a
concomitant contact allergy with regard to whole saliva and parotid
saliva flow rates (Larsen, Johansen, Reibel, Zachariae, & Pedersen,
2017; Larsen, Johansen, Reibel, Zachariae, Rosing et al., 2017).
All patients reported various oral symptoms related to their oral
lesions (Table 1). The most prevalent symptoms were stinging,
stabbing, and burning, and patients often reported more than one
symptom. There was no difference between the patient groups with
regard to symptoms and the number of symptoms reported.
TABLE 1 Demographic and medical data of the patients with OLP, OLL, and stomatitis
OLP (n = 19) OLL (n = 19) Stomatitis (n = 11)
Age, mean ± SD (range), years 60.2 ± 10.3 (46–73) 59.1 ± 10.3 (31–75) 65.5 ± 9.4 (48–77)
Gender (female : male ratio) 17:2 16:3 10:1
Smokers 1 1 1
No. of medical diseases, median 2 2 2
No. of medications, median 2 2 2
Contact allergy 6 9 4
Active dermatoses, not LP (%) 20.4 21.1 18.2
Xerostomia (varying severity) 7 9 6
Taste disturbances 7 3 4
Other oral symptomsa
Stinging, stabbing, burning 17 13 11
Roughness of the oral mucosa 14 15 3
Abrasion of the oral mucosa 6 14 4
Ulceration of the oral mucosa 6 12 4
Blisters in the oral mucosa 7 4 1
Peeling of the oral epithelium 3 14 2
Note. OLP = oral lichen planus; OLL = oral lichenoid lesions; LP = lichen planus.
aSome patients had more than one symptom
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observed in the patients is presented in Tables 2 and 3, respectively.
The most common site for oral lesions was the buccal mucosa. There
was no difference between the patient groups with regard to the site
of lesions, but in OLP, the lesions were more or less symmetrical. There
were no associations between age, gender, symptoms, site, or type of
the oral lesions. However, patients with lesions on the gingivae tended
to havemore oral symptoms. As only a few of the patientswere smokers,TABLE 2 The clinical pattern of the oral lesions in patients with OLP,
OLL, and stomatitis
OLP
(n = 19)
OLL
(n = 19)
Stomatitis
(n = 11)
Clinical pattern
Reticular (lacelike network of
slightly raised gray‐white lines)
19 19 5
Erosive or ulcerative 1 3 0
Plaquelike 2 2 0
Erythematous or atrophic 16 13 11
Bullous 0 0 0
Papular 0 0 0
Site of lesionsa
Buccal mucosa 14 17 6
Gingivae 13 15 5
Tongue 8 5 4
Alveolar buccal sulcus 8 11 2
Palate 3 4 3
Labial mucosa 6 4 8
Floor of the mouth 1 0 1
Note. OLP = oral lichen planus; OLL = oral lichenoid lesions.
aSome patients had combinations of lesions and lesions at more than one
site.we did not find any association to the clinical pattern of the lesion and
smoking. In general, discrimination between OLP, OLL, and generalized
stomatitis based on the clinical observations was very difficult.
In general, the levels of the serum cytokines displayed large varia-
tions (Table 4). Serum levels of IL‐6 was significantly higher in the
patients than in the healthy control subjects (p = .048), whereasTNF‐α
and IL‐10 did not differ. There was no statistical significance in the
serum levels of TNF‐α, IL‐6, and IL‐10 between the patients with
OLP, OLL, and generalized stomatitis and those with and without
concomitant contact allergy. All measured serum levels of IL‐12p40
and INF‐γ were below the limit of detection. Serum IL‐12p70 could
only be detected in a single patient.4 | DISCUSSION
The aim of this cross‐sectional study was to determine whether the
clinical and histopathological characteristics of OLP, OLL, and
stomatitis can be reflected in differences in the profile of serum
cytokines, and also whether the presence of concomitant allergy
influence the levels of selected circulating cytokines. Findings were
compared between the various patient groups and also between
the patients and the healthy control subjects. Presently, discrimina-
tion between OLP and OLL is difficult based on the clinical features,
and in some cases, also with regard to the histopathological features,
and there is a need to identify markers that can be helpful in this
discrimination.
The results of our study did not demonstrate any significant
differences in the serum levels of cytokines tested nor between
patients with OLP, OLL, and generalized stomatitis or patients with
or without contact allergy. Furthermore, only the serum levels of IL‐6
were significantly higher in the patients as a whole when compared
to the healthy control group. We found no associations between the
TABLE 3 Histopathological characteristics of the oral lesions in patients with OLP, OLL, and stomatitis
OLP
(n = 19)
OLL
(n = 19)
Stomatitis
(n = 11)
Histopathological characteristics
Hyperortho‐ or hyperparakeratosis 19 19 6
Saw‐tooth rete ridges 8 1 0
Civatte bodies or single cell necrosis 9 6 1 or 0
Band of eosinophilic material 12 9 0
Well‐defined, bandlike zone of cellular infiltration of mainly lymphocytes confined to the superficial lamina propria 19 0 0
Liquefaction degeneration in the basal layer 14 8 1
Epithelial atrophy 17 13 3
Epithelial hyperplasia 2 0 1
Diffuse chronic inflammation 3 11 3
Note. OLP = oral lichen planus; OLL = oral lichenoid lesions.
TABLE 4 Serum levels of IL‐6, IL‐10, IL‐12p40, IL‐12p70, TNF‐α, and INF‐γ measured in pg/ml
OLP OLL Stomatitis Healthy controls
IL‐6 89.6 ± 300.7 50.7 ± 128.3 49.8 ± 106.2 48.3 ± 128.0
IL‐10 4617.6 ± 1806.2 366.7 ± 876.2 464.1 ± 549.4 763.3 ± 2396.8
IL‐12p40 Below limit of detection Below limit of detection Below limit of detection Below limit of detection
IL‐12p70 One sample Below limit of detection Below limit of detection Below limit of detection
TNF‐α 645.9 ± 1597.4 760.3 ± 1563.8 246 ± 179.6 Below limit of detection
INF‐γ Below limit of detection Below limit of detection Below limit of detection Below limit of detection
Note. All data are given in mean and SD. OLP = oral lichen planus; OLL = oral lichenoid lesions.
224 ROEN ET AL.clinical pattern of oral lesions and the histopathological features and
age, gender, oral symptoms, and serum cytokines.
Several studies have shown that the cytokine profile in saliva,
lesions, and serum of patients with OLP differs from that seen in
healthy individuals (Dan et al., 2011; de Brito Monteiro et al.,
2015; Kaur & Jacobs, 2015; Kondo & Urisu, 2009; Liu et al., 2014;
Lu et al., 2013; Malekzadeh et al., 2015; Pekiner et al., 2012;
Piccinni et al., 2014; Simark‐Mattsson et al., 1999; Wang et al.,
2015; Zhou et al., 2009). In this study, we found that the serum
levels of IL‐6 were higher in the patients than in the healthy control
subjects and in accordance with previous findings that also found an
association between levels of IL‐6 and the stages of OLP (Abdel‐Haq
et al., 2014; Kaur & Jacobs, 2015). In our study, the majority of
patients (15 out of 19) had erosive or ulcerative OLP lesions at
the time of examination.
In this study, we found no difference in the serum levels of TNF‐α
and IL‐10 between the patients groups and between the patients and
healthy control subjects. The results of previous studies on TNF‐α are
conflicting, although mostly showing elevated levels in patients with
OLP compared to healthy controls (Kaur & Jacobs, 2015; Kondo &
Urisu, 2009; Lu et al., 2013; Pekiner et al., 2012; Simark‐Mattsson
et al., 1999; Zhou et al., 2009). The serum levels of IL‐10 has been
found increased in patients with OLP (Dan et al., 2011; Pekiner et al.,
2012) but also decreased (Lu et al., 2013). The levels of INF‐γ,
IL‐12p40, and IL‐12p70 were below the detection limit. Previous
studies have shown inconsistent results regarding serum levels of
INF‐γ in patients with OLP, reporting both higher (Hu et al., 2013)and no difference compared to healthy controls (Pekiner et al.,
2012). Studies on IL‐12 are limited and have shown conflicting results.
Ohno et al. (2011) reported in 2011 higher production of IL‐12 by
PBMCs from patients with OLP than in those from healthy control
subjects. A higher production of IL‐12 has also been shown in the
salivary epithelial cells from patients with OLP compared to those
from healthy control subjects (Janardhanam et al., 2012), whereas
another study found decreased number of IL‐12‐secreting T cells in
peripheral blood of patients with OLP when compared to healthy
control subjects (Kalogerakou, Albanidou‐Farmaki, Markopoulos, &
Antoniades, 2008).
All patients had oral symptoms and mainly symptoms of stab-
bing, stinging and burning, and also a high frequency of xerostomia.
In addition, the patients reported a high number of medical condi-
tions and intake of medication, which is accordance with previous
studies showing that women, and especially above the age of
65 years, have more medical diseases, a higher intake of medications
and report more symptoms than men (Smidt, Torpet, Nauntofte,
Heegaard, & Pedersen, 2011). OLP is estimated to be twice as
common in women as in men, but in this study, the ratio was
significantly higher (6:1) (Kovac‐Kovacic & Skaleric, 2000; Scully
et al., 1998). The age of the patients is in accordance with findings
of previous studies showing that OLP and OLL often occur at the
average age of 60 years (Kovac‐Kovacic & Skaleric, 2000; Scully
et al., 1998). The age of onset also suggest that gender hormones
may be involved in the pathogenesis by making the mucosa more
susceptible to oral diseases such as OLP and allergic reactions.
ROEN ET AL. 2255 | CONCLUSION
In our study the serum levels of TNF‐α, INF‐γ, IL‐6, IL‐10, IL‐12p40,
and IL‐12p70 were not useful in the discrimination between OLP,
OLL, and generalized stomatitis and between these conditions with
or without contact allergic reactions.
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